Clearmind Medicine Inc. (CMND)

NASDAQ: CMND · IEX Real-Time Price · USD
1.590
+0.060 (3.92%)
At close: Mar 1, 2024, 4:00 PM
1.570
-0.020 (-1.26%)
After-hours: Mar 1, 2024, 7:59 PM EST
3.92%
Market Cap 5.17M
Revenue (ttm) n/a
Net Income (ttm) -8.62M
Shares Out 3.17M
EPS (ttm) -31.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 77,376
Open 1.565
Previous Close 1.530
Day's Range 1.450 - 1.594
52-Week Range 0.921 - 151.260
Beta 1.56
Analysts n/a
Price Target n/a
Earnings Date Mar 12, 2024

About CMND

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country Canada
Stock Exchange NASDAQ
Ticker Symbol CMND
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements

News

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

New patent applications build upon Clearmind's broad IP protection in the psychedelic space Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY0...

5 days ago - GlobeNewsWire

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI

9 days ago - GlobeNewsWire

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Vancouver, Canada, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of n...

12 days ago - GlobeNewsWire

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

Tel Aviv, Israel / Vancouver, Canada, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery a...

27 days ago - GlobeNewsWire

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

The licensing agreement refers to the company's dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving

4 weeks ago - GlobeNewsWire

Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)

NEW YORK, NY / ACCESSWIRE / January 16, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ:CMND). About C...

6 weeks ago - Accesswire

Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement

TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (the “Company”), a biotech company focused on discovery and development of novel psychede...

6 weeks ago - GlobeNewsWire

Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement

TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (the “Company”), a biotech company focused on discovery and development of novel psychede...

7 weeks ago - GlobeNewsWire

Clearmind Medicine Completed Type A Meeting with the FDA

Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery a...

7 weeks ago - GlobeNewsWire

Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments

The collaboration included filing six different US patent applications with the United States Patent and Trademark Office to protect novel combinations of psychedelics with SciSparc's PEA

2 months ago - GlobeNewsWire

Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards

Nasdaq Has Informed the Company That a Bid Price Deficiency of its Common Shares Has Been Cured Tel Aviv, Israel / Vancouver, Canada, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq,...

2 months ago - GlobeNewsWire

Clearmind Medicine Inc (CMND) is the goose that got cooked – trade carefully

Clearmind Medicine Inc. (NASDAQ:CMND) is on the move this week after favourable stock market news. The company dedicates its resources to discovering a cure for cocaine addiction.

3 months ago - Invezz

Weight loss MEAI: Clearmind Medicine's Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial

The collaboration between Clearmind and SciSparc continues to yield positive results in its obesity and Metabolic disorder program

3 months ago - GlobeNewsWire

Clearmind Medicine (CMND) stock price is flying but risks remain

Clearmind Medicine (NASDAQ: CMND) stock price was among the best-performing in Wall Street on Thursday. The share jumped by more than 32% and reached a high of $5.37.

3 months ago - Invezz

Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment

Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite

3 months ago - GlobeNewsWire

Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures

Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and changing international psychedelic space

3 months ago - GlobeNewsWire

Clearmind Medicine Announces 1-for-30 Reverse Share Split

Following the reverse share split, the Company will have 607,381 Ordinary Shares issued and outstanding Tel Aviv, Israel / Vancouver, Canada, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ...

3 months ago - GlobeNewsWire

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance

As part of the Company's plan for recompliance, the Company's shareholders approved a reverse stock split on November 14, 2023. Tel Aviv, Israel / Vancouver, Canada, Nov. 17, 2023 (GLOBE NEWSWIRE) -- ...

3 months ago - GlobeNewsWire

Clearmind Medicine Announces Shareholders Meeting Results

Tel Aviv, Israel / Vancouver, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery a...

3 months ago - GlobeNewsWire

Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial

4 months ago - GlobeNewsWire

Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th

Tel Aviv, Israel / Vancouver, Canada, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery a...

5 months ago - GlobeNewsWire

Clearmind Medicine to Present at the LD Micro Main Event XVI Investor Conference on October 4th

Tel Aviv, Israel and Vancouver, British Columbia--(Newsfile Corp. - September 28, 2023) - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY) ("Clearmind" or the "company"), a biotech compan...

5 months ago - Newsfile Corp

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND)

NEW YORK, NY / ACCESSWIRE / September 19, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND). About Clearmind Me...

5 months ago - Accesswire

Clearmind Medicine Closes US$2.25 Million Public Offering

Tel Aviv, Israel / Vancouver, Canada, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and de...

5 months ago - GlobeNewsWire

Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

Tel Aviv, Israel / Vancouver, Canada, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and de...

6 months ago - GlobeNewsWire